Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life (Ex Stress II)
Primary Purpose
Life Stress, Fatigue, Pain
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Extramel 10 mg - 140 UI SOD
Placebo - Excipient only
Sponsored by
About this trial
This is an interventional supportive care trial for Life Stress focused on measuring Super-Oxyd-Dismutase, SOD, melon juce, perceived stress
Eligibility Criteria
Inclusion Criteria:
- Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the inclusion visit for the women of reproductive age.
- Older than 30 years and younger than 65 years
- BMI ≤ 30
- Score greater than 30 on the Cohen perceived stress scale PSS 14.
- Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits).
Presenting an impact of stress on at least one of the following domains.
- pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale,
- physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale,
- the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test.
- Stable professional activity since at least 1 year.
- Completely healthy on the day of inclusion, and not taking any medicinal product or dietary supplement with an anti-stress or anti-pain objective.
- Not taking any herbal tea or drink with an anti-stress or anti-pain objective.
- Accepting not to modify his/her dietary habits.
- Having given his/her free, informed and express consent.
- Capable of understanding the nature of the objectives, the consequences of the study and accepting to comply with the protocol requirements.
- Affiliated with a social security insurance or beneficiary of such an insurance system.
Exclusion Criteria:
- Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician.
- Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment.
- Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment.
- Pregnant and/or breast-feeding women.
- Any person who does not satisfy by definition the inclusion criteria.
- Adult protected by the law.
- Any history of psychiatric disease.
- Any pathology in progress or active in the previous month.
- Any administration of a dietary supplement in progress or in the previous month.
- Any subject who within the 3 months following inclusion is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Extramel 10 mg - 140 UI SOD
Placebo - exipients only
Arm Description
This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
This arm receives daily one capsule Placebo containing excipients only.
Outcomes
Primary Outcome Measures
Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3
Evaluation performed by Cohen PSS 14 scale. It should be noted that in order to be included the patient had to present a minimum score of 30 on the Cohen scale.
Secondary Outcome Measures
Evaluation of evolution of Physical fatigue
Evaluation performed by Prevost subjective fatigue scale and Ruffier test.
Evaluation of evolution of Intellectual fatigue
Evaluation performed by Stroop test, Reverse Stroop test and 15-words Rey test.
Evaluation of evolution of pain
Evaluation of subjects' perceived chronic pain (if existing), was performed using a simple visual analog scale (VAS).
Evaluation of evolution of subject Quality of life
Evaluation of subjects' quality of life, was performed by using Quality of Life SF36 scale.
Evaluation of evolution of subject Quality of life
Evaluation of subjects' quality of life, was performed by using Hamilton anxiety scale.
Evaluation of evolution of subject Quality of life
Evaluation of subjects' quality of life, was performed by using Personnal stress profile questionnary.
Full Information
NCT ID
NCT01767922
First Posted
January 11, 2013
Last Updated
January 17, 2013
Sponsor
Bionov
Collaborators
Seppic
1. Study Identification
Unique Protocol Identification Number
NCT01767922
Brief Title
Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life
Acronym
Ex Stress II
Official Title
Multicentre, Double-blind Study Versus Placebo on the Impact and Safety of the Daily Administration of Extramel® 140 IU for 12 Weeks on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception, if Present, and the Impact on the Quality of Life of 70 Subjects Included, of Which 60 That Can be Evaluated
Study Type
Interventional
2. Study Status
Record Verification Date
January 2013
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
May 2009 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bionov
Collaborators
Seppic
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Objectives of this Multicentre, double-blind study versus placebo were to evaluate impact and safety of the daily administration of Extramel® 140 IU SOD for 12 weeks on perceived stress, physical and intellectual fatigue, pain perception, if present, and the impact on the quality of life of 70 subjects included with 60 that can be evaluated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Life Stress, Fatigue, Pain, Quality of Life
Keywords
Super-Oxyd-Dismutase, SOD, melon juce, perceived stress
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
61 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Extramel 10 mg - 140 UI SOD
Arm Type
Experimental
Arm Description
This arm receives daily one capsule Extramel 10 mg containing 140 UI of SOD.
Arm Title
Placebo - exipients only
Arm Type
Placebo Comparator
Arm Description
This arm receives daily one capsule Placebo containing excipients only.
Intervention Type
Dietary Supplement
Intervention Name(s)
Extramel 10 mg - 140 UI SOD
Intervention Description
Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.
Each volunteer was seen for the 3 visits:
visit V1, so-called inclusion visit (D0),
visit V2 at 28 days, tolerance of +/- 3 days, (D28) and
visit V3 at 84 days, tolerance of +/- 3 days, (D84).
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo - Excipient only
Primary Outcome Measure Information:
Title
Perceived Stress : Change from base line in Cohen PSS 14 scale at V2 and V3
Description
Evaluation performed by Cohen PSS 14 scale. It should be noted that in order to be included the patient had to present a minimum score of 30 on the Cohen scale.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Secondary Outcome Measure Information:
Title
Evaluation of evolution of Physical fatigue
Description
Evaluation performed by Prevost subjective fatigue scale and Ruffier test.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Title
Evaluation of evolution of Intellectual fatigue
Description
Evaluation performed by Stroop test, Reverse Stroop test and 15-words Rey test.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Title
Evaluation of evolution of pain
Description
Evaluation of subjects' perceived chronic pain (if existing), was performed using a simple visual analog scale (VAS).
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Title
Evaluation of evolution of subject Quality of life
Description
Evaluation of subjects' quality of life, was performed by using Quality of Life SF36 scale.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Title
Evaluation of evolution of subject Quality of life
Description
Evaluation of subjects' quality of life, was performed by using Hamilton anxiety scale.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Title
Evaluation of evolution of subject Quality of life
Description
Evaluation of subjects' quality of life, was performed by using Personnal stress profile questionnary.
Time Frame
Evaluation performed at inclusion day (V1), after 4 weeks at D28 (V2) and then at the end of study visit on D84 (V3).
Other Pre-specified Outcome Measures:
Title
Evaluation of safety
Description
Assessment of the safety performed by analysis of adverse events that occurred throughout the study.
Time Frame
Global safty evaluation performed at the end of study.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Male or female person using an effective contraceptive method, with a negative urine pregnancy test on the inclusion visit for the women of reproductive age.
Older than 30 years and younger than 65 years
BMI ≤ 30
Score greater than 30 on the Cohen perceived stress scale PSS 14.
Score between 5 and 20 in the Hamilton anxiety scale (excluding the limits).
Presenting an impact of stress on at least one of the following domains.
pain domain with a score greater than 20 millimeters measured on the visual pain evaluation scale,
physical condition domain with a score greater than 50 on the Prevost subjective fatigue scale,
the psychical condition domain with a global score below 160 in the Stroop test and the reverse Stroop test.
Stable professional activity since at least 1 year.
Completely healthy on the day of inclusion, and not taking any medicinal product or dietary supplement with an anti-stress or anti-pain objective.
Not taking any herbal tea or drink with an anti-stress or anti-pain objective.
Accepting not to modify his/her dietary habits.
Having given his/her free, informed and express consent.
Capable of understanding the nature of the objectives, the consequences of the study and accepting to comply with the protocol requirements.
Affiliated with a social security insurance or beneficiary of such an insurance system.
Exclusion Criteria:
Subject presenting an acute pain or pain considered to be incapacitating by the patient him/herself or the observer physician.
Subject currently under a chronic or acute treatment indicated for stress or anxiety, irrespective of the treatment.
Subject currently under a chronic or acute treatment indicated for pain problems, irrespective of the treatment.
Pregnant and/or breast-feeding women.
Any person who does not satisfy by definition the inclusion criteria.
Adult protected by the law.
Any history of psychiatric disease.
Any pathology in progress or active in the previous month.
Any administration of a dietary supplement in progress or in the previous month.
Any subject who within the 3 months following inclusion is likely to experience a major modification of his/her life rhythm (For example marriage, birth of a child, scheduled hospitalization, important exam, etc.) this is left to the discretion of the investigator.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thierry CANTIN, MD
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Patrick LEPRINCE, MD
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Hubert TAUPE, PharmD
Organizational Affiliation
ISOCLIN
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
24949549
Citation
Carillon J, Notin C, Schmitt K, Simoneau G, Lacan D. Dietary supplementation with a superoxide dismutase-melon concentrate reduces stress, physical and mental fatigue in healthy people: a randomised, double-blind, placebo-controlled trial. Nutrients. 2014 Jun 19;6(6):2348-59. doi: 10.3390/nu6062348.
Results Reference
derived
Learn more about this trial
Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life
We'll reach out to this number within 24 hrs